stockportfolio.pro
Bicara Therapeutics Inc. (BCAX)
Healthcare · Biotechnology · NasdaqGM
Bicara Therapeutics Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — |
| Net income | $-37.84M | $-51.98M | $-68.00M | $-137.95M |
| Net margin | — | — | — | — |
Source: Bicara Therapeutics Inc. SEC filings (10-K).
Explore 4 years of Bicara Therapeutics Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track BCAX in your portfolio →
Bicara Therapeutics Inc. financial history by metric
About Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Bicara Therapeutics Inc. — frequently asked questions
What is Bicara Therapeutics Inc.'s revenue?
Bicara Therapeutics Inc. (BCAX) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Bicara Therapeutics Inc. profitable?
No — BCAX reported a net loss of $-137.95M in fiscal 2025.
What is BCAX's P/E ratio?
Bicara Therapeutics Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Bicara Therapeutics Inc. have?
As of fiscal year 2025, BCAX carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Bicara Therapeutics Inc.'s market cap?
Bicara Therapeutics Inc. (BCAX) has a market capitalization of about $1.37B, based on the latest data in our nightly-refreshed cache.
When does Bicara Therapeutics Inc.'s fiscal year end?
BCAX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Bicara Therapeutics Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.